MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline
- 27 Jun 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Planned End Date changed from 30 May 2017 to 1 Jun 2017.
- 01 Jun 2017 Planned primary completion date changed from 30 May 2017 to 1 Jun 2017.